Capstone Therapeutics Statistics
Share Statistics
Capstone Therapeutics has 5.19M
shares outstanding. The number of shares has increased by 2488.23%
in one year.
| Shares Outstanding | 5.19M |
| Shares Change (YoY) | 2488.23% |
| Shares Change (QoQ) | 2488.23% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 25.23K, so 0.49% of the outstanding
shares have been sold short.
| Short Interest | 25.23K |
| Short % of Shares Out | 0.49% |
| Short % of Float | 1.58% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.14 and the forward
PE ratio is null.
Capstone Therapeutics's PEG ratio is
0.03.
| PE Ratio | -0.14 |
| Forward PE | n/a |
| PS Ratio | 0.01 |
| Forward PS | 0.2 |
| PB Ratio | -0.12 |
| P/FCF Ratio | 0.1 |
| PEG Ratio | 0.03 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Capstone Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.02,
with a Debt / Equity ratio of -5.43.
| Current Ratio | 1.02 |
| Quick Ratio | 0.27 |
| Debt / Equity | -5.43 |
| Debt / EBITDA | -137.29 |
| Debt / FCF | 4.49 |
| Interest Coverage | -0.43 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,246,555.56 |
| Profits Per Employee | $-71,194.44 |
| Employee Count | 36 |
| Asset Turnover | 0.95 |
| Inventory Turnover | 3.73 |
Taxes
| Income Tax | -442K |
| Effective Tax Rate | 7.44% |
Stock Price Statistics
The stock price has increased by -57.45% in the
last 52 weeks. The beta is -0.82, so Capstone Therapeutics's
price volatility has been lower than the market average.
| Beta | -0.82 |
| 52-Week Price Change | -57.45% |
| 50-Day Moving Average | 2.15 |
| 200-Day Moving Average | 3 |
| Relative Strength Index (RSI) | 48.25 |
| Average Volume (20 Days) | 708,530 |
Income Statement
In the last 12 months, Capstone Therapeutics had revenue of 44.88M
and earned -2.56M
in profits. Earnings per share was -34.86.
| Revenue | 44.88M |
| Gross Profit | 9.57M |
| Operating Income | -638K |
| Net Income | -2.56M |
| EBITDA | -121K |
| EBIT | -638K |
| Earnings Per Share (EPS) | -34.86 |
Full Income StatementBalance Sheet
The company has 11K in cash and 16.61M in
debt, giving a net cash position of -16.6M.
| Cash & Cash Equivalents | 11K |
| Total Debt | 16.61M |
| Net Cash | -16.6M |
| Retained Earnings | -196.1M |
| Total Assets | 35.5M |
| Working Capital | 2.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 3.82M
and capital expenditures -120K, giving a free cash flow of 3.7M.
| Operating Cash Flow | 3.82M |
| Capital Expenditures | -120K |
| Free Cash Flow | 3.7M |
| FCF Per Share | 23.48 |
Full Cash Flow StatementMargins
Gross margin is 21.33%, with operating and profit margins of -1.42% and -5.71%.
| Gross Margin | 21.33% |
| Operating Margin | -1.42% |
| Pretax Margin | -13.23% |
| Profit Margin | -5.71% |
| EBITDA Margin | -0.27% |
| EBIT Margin | -1.42% |
| FCF Margin | 8.25% |
